Abstract
Alzheimer’s Disease (AD) is a neurodegenerative disease. The disease itself
is progressive and full recovery from it isn’t achievable yet. There are several
hypotheses asserted (Cholinergic hypothesis, Amyloid hypothesis etc.) to explain the
mechanisms behind the disease. Also, many targets have been identified for possible
therapeutics and from these targets, numerous drug candidates have been evaluated in
clinical trials. Unfortunately, most of these trials failed due to the enigmatic nature of
this disease. Currently, there are 7103 targets associated with Alzheimer's disease listed
in the Open Targets platform where 1240 of them are enzyme-related. In this chapter,
enzymatic targets of the AD have been reviewed, and those claimed to have disease modifying effects were selected and presented according to their clinical significance.
Related Journals
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry
Drug Delivery Letters
Recent Advances in Anti-Infective Drug Discovery
Applied Drug Research, Clinical Trials and Regulatory Affairs
Current Bioactive Compounds
Current Drug Delivery
Current Drug Safety
Drug Metabolism and Bioanalysis Letters
Recent Advances in Drug Delivery and Formulation
Reviews on Recent Clinical Trials
Related Books
Biotechnology and Drug Development for Targeting Human Diseases
4th International Conference on Drug Discovery and Therapy - 2012
Applied Computer-Aided Drug Design: Models and Methods
Computational Toxicology for Drug Safety and a Sustainable Environment
Nanotechnology in Drug Discovery
AI Innovations in Drug Delivery and Pharmaceutical Sciences; Advancing Therapy through Technology
A Comprehensive Text Book on Self-emulsifying Drug Delivery Systems
Angiogenesis & Therapeutic Targets In Cancer
Anti-Angiogenesis Drug Discovery and Development
Anti-Angiogenesis Drug Discovery and Development